Therapeutic strategies for psoriasis

Journal of Clinical Pharmacy and Therapeutics

Volumn 25, Issue 1, 2000, Pages 1-10

  Ashcroft, D M ^a   Li Wan Po, Alain ^a   Griffiths, C E M ^b  

^a ASTON UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIPSORIASIS AGENT; BERGAPTEN; CALCIPOTRIOL; CALCIUM CHANNEL BLOCKING AGENT; COAL TAR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DILTIAZEM; DITHRANOL; EMOLLIENT AGENT; ETRETIN; HYDROXYUREA; METHOTREXATE; METHOXSALEN; NICARDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PENICILLIN G; PROBENECID; PSORALEN; SALICYLIC ACID; TAZAROTENE; TRIMETHOPRIM;

ABDOMINAL PAIN; ACNE; ADRENAL SUPPRESSION; ALOPECIA; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; DIARRHEA; DRUG SENSITIZATION; ERYTHEMA; GINGIVA HYPERPLASIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOPIGMENTATION; LIVER TOXICITY; MORBIDITY; NAUSEA; NEPHROTOXICITY; PERIORAL DERMATITIS; PHOTOTHERAPY; PRURITUS; PSORIASIS; PUVA; QUALITY OF LIFE; REVIEW; SKIN ATROPHY; SKIN CANCER; SKIN IRRITATION; TELANGIECTASIA; TREMOR; ULTRAVIOLET B RADIATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; DRUG THERAPY; HUMANS; PHOTOTHERAPY; PROGNOSIS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 0034024909     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2000.00254.x     Document Type: Review

References (38)

1. 1. Nevitt GJ, Hutchinson PE. (1996) Psoriasis in the community: prevalence severity and patients' beliefs and attitudes towards the disease. British Journal of Dermatology, 135, 533-537.
2. 2. Rea JN, Newhouse ML, Halil T. (1976) Skin disease in Lambeth. A community study of prevalence and use of medical care. British Journal of Preventative Medicine, 30, 107-114.
3. 3. Johnson M. (1971-74) Skin conditions and related need for medical care among persons 1-74 years. United States. Vital and Health Statistics. Series 11. Data from the National Health Survey. November 1978.
4. 4. Camisa C, (1994) Psoriasis. Blackwell Scientific, Boston.
5. 5. Swanbeck G, Inerot A, Martinsson T, et al (1997) Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. British Journal of Dermatology, 137, 939-942.
6. 6. Farber EM, Nail ML. (1971) Genetics of psoriasis: twin study. In: Farber EM, Cox AJ eds. Psoriasis: Proceedings of the International Symposium. Stanford, California: Stanford University Press, 7-13.
7. 7. Tiilikainen A, Lassus A, Karvonen J, et al. (1980) Psoriasis and HLA-Cw6. British Journal of Dermatology, 102, 179-180.
8. 8. Henseler T, Christophers E. (1985) Psoriasis of early and late onset. Characterization of two types of psoriasis vulgaris. Journal of the American Academy of Dermatology, 13, 450-456.
9. 9. Ortonne JP. (1996) Aetiology and pathogenesis of psoriasis. British Journal of Dermatology, 135 (Suppl. 49), 1-5.
10. 10. Greaves MW, Weinstein GD. (1995) Treatment of psoriasis. New England Journal of Medicine, 332, 581-588.
11. 11. Watsky KL, Freije L, Leneveu MC, Wenck HA, Leffell DJ. (1992) Water-in-oil emollients as steroid-sparing adjunctive therapy in the treatment of psoriasis. Cutis, 50, 383-386.
12. 12. Penneys NS, Eaglestein W, Ziboh V. (1980) Petrolatum: interference with the oxidation of arachidonjc acid. British Journal of Dermatology, 103, 257-262.
13. 13. Gawkrodger DJ. on behalf of the Therapy Guidelines and Audit Subcommittee of the British Association of Dermatologists. (1997) Current management of psoriasis. Journal of Dermatological Treatment, 8, 27-55.
14. 14. Kanzler MH, Gorsulowsky DC. (1993) Efficacy of topical 5% liquor carbonis detergens vs. its emollient base in the treatment of psoriasis. British Journal of Dermatology, 129, 310-314.
15. 15. van Schooten FJ, Moonen EJC, Rhijnsburger E, et al. (1995) Dermal uptake of polycyclic aromatic hydrocarbons after hairwash with coal-tar shampoo. Lancet, 344, 1505-1506
16. 16. Ryatt KS, Statham BN, Rowell NR. (1984) Short-contact modification of the Ingram regime. British Journal of Dermatology, 111, 455-459.
17. 17. Liem WH, McCullough J, Weinstein GD. (1992) Is topical therapy eftective for psoriasis: results of a survey of US dermatologists. Journal of Investigative Dermatology 98 602.
18. 18. Lagos BR, Maibach HI. (1998) Frequency of application of topical corticosteroids: an overview. British Journal of Dermatology, 139, 763-766.
19. 19. Katz HI. (1995) Topical corticosteroids. Dermatology Clinics, 13, 805-815.
20. 3. Medical Journal of Osaka University, 35, 51.
21. 21. Bourke JF, Berth-Jones J, Hutchinson PE. (1993) High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. British Journal of Dermatology, 129, 74-76.
22. 22. Duvic M, Nagpal S, Asano At, et al. (1997) Molecular mechanisms of tazarotene action in psoriasis. Journal of the American Academy of Dermatology, 37, S18-S24.
23. 23. Stern RS, Armstrong RB, Anderson TF, et al. (1986) Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomised study. Journal of the American Academy of Dermatology, 15, 546-552.
24. 24. Williams REA. (1991) Guidelines for the management of patients with psoriasis. British Medical Journal, 303, 829-835.
25. 25. British Photodermatology Group. (1997) An appraisal of narrowband (TL-01) UVB phototherapy. British Journal of Dermatology, 137, 327-330.
26. 26. British Photodermatology Group. (1994) British Photodermatology Group guidelines for PUVA. British Journal of Dermatology, 130, 246-255.
27. 27. Wolff K. (1990) Side-effects of psoralen photochemotherapy (PUVA). British Journal of Dermatology, 122(Suppl. 36), 117-125.
28. 28. Stern RS, Laird N. (1994) The carcinogenic risk of treatments for severe psoriasis. Cancer, 73, 2759-2764.
29. 29. Stern RS, Nichols KT, Väkevä LH. (1997) Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). New England Journal of Medicine, 336, 1041-1045.
30. 30. Roenigk HH, Auerbach R, Maibach HI, Weinstein GD. (1988) Methotrexate in psoriasis: revised guidelines. Journal of the American Academy of Dermatology, 19, 145-156.
31. 31. Boffa MJ, Chalmers RJG. (1996) Methotrexate for psoriasis. Clinical Experimental Dermatology, 21, 399-408.
32. 32. Committee on Safety of Medicines. (1997) Current Problems in Pharmacovigilance, 23, 9-12.
33. 33. Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen S. (1997) Renal biopsy findings in long-term cyclosporin treatment of psoriasis. British Journal of Dermatology, 136, 531-535.
34. 34. Iest J, Boer J. (1989) Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acirretin alone and UVB alone. British Journal of Dermatology, 120, 665-670.
35. 35. Halioua B, Saurat JH. (1990) Risk: benefit ratio in the treatment of psoriasis with systemic retinoids. British Journal of Dermatology, 122 (Suppl 36), 135-150.
36. 36. Gollnick HPM. (1996) Oral retinoids - efficacy and toxicity in psoriasis. British Journal of Dermatolology, 135 (Suppl 49), 6-17.
37. 37. Boyd AS, Neidner KH. (1991) Hydroxyurea therapy. Journal of American Academy of Dermatology, 25, 518-524.
38. 38. Asadhullah K, D'cke W-D, Ebeling M, et al. (1999) Interleukin 10 treatment of psoriasis. Archives of Dermatology, 13, 187-192.